Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

APOBEC3G: a double agent in defense.

Smith HC.

Trends Biochem Sci. 2011 May;36(5):239-44. doi: 10.1016/j.tibs.2010.12.003. Epub 2011 Jan 14.

2.

Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Pery E, Sheehy A, Nebane NM, Brazier AJ, Misra V, Rajendran KS, Buhrlage SJ, Mankowski MK, Rasmussen L, White EL, Ptak RG, Gabuzda D.

J Biol Chem. 2015 Apr 17;290(16):10504-17. doi: 10.1074/jbc.M114.626903. Epub 2015 Feb 27.

3.

Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.

Zuo T, Liu D, Lv W, Wang X, Wang J, Lv M, Huang W, Wu J, Zhang H, Jin H, Zhang L, Kong W, Yu X.

J Virol. 2012 May;86(10):5497-507. doi: 10.1128/JVI.06957-11. Epub 2012 Feb 29.

4.

APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated.

Dang Y, Siew LM, Zheng YH.

J Biol Chem. 2008 May 9;283(19):13124-31. doi: 10.1074/jbc.M708728200. Epub 2008 Mar 6.

5.
6.

APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.

Krisko JF, Begum N, Baker CE, Foster JL, Garcia JV.

J Virol. 2016 Apr 14;90(9):4681-95. doi: 10.1128/JVI.03275-15. Print 2016 May.

PMID:
26912618
7.

Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy.

Hosseini I, Mac Gabhann F.

PLoS Comput Biol. 2012 Feb;8(2):e1002371. doi: 10.1371/journal.pcbi.1002371. Epub 2012 Feb 9.

8.

Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.

Sugiyama R, Abe M, Nishitsuji H, Murakami Y, Takeuchi H, Takaku H.

Antiviral Res. 2013 Sep;99(3):307-11. doi: 10.1016/j.antiviral.2013.06.017. Epub 2013 Jul 4.

PMID:
23831493
9.

The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.

Donahue JP, Vetter ML, Mukhtar NA, D'Aquila RT.

Virology. 2008 Jul 20;377(1):49-53. doi: 10.1016/j.virol.2008.04.017. Epub 2008 May 21.

10.

The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.

Casartelli N, Guivel-Benhassine F, Bouziat R, Brandler S, Schwartz O, Moris A.

J Exp Med. 2010 Jan 18;207(1):39-49. doi: 10.1084/jem.20091933. Epub 2009 Dec 28.

11.

Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.

Jäger S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ.

Nature. 2011 Dec 21;481(7381):371-5. doi: 10.1038/nature10693.

12.

Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.

Dang Y, Wang X, York IA, Zheng YH.

J Virol. 2010 Sep;84(17):8561-70. doi: 10.1128/JVI.00960-10. Epub 2010 Jun 30.

13.

The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Binka M, Ooms M, Steward M, Simon V.

J Virol. 2012 Jan;86(1):49-59. doi: 10.1128/JVI.06082-11. Epub 2011 Oct 19.

14.

HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain.

Iwatani Y, Chan DS, Liu L, Yoshii H, Shibata J, Yamamoto N, Levin JG, Gronenborn AM, Sugiura W.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19539-44. doi: 10.1073/pnas.0906652106. Epub 2009 Nov 3.

15.

Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection.

Thangavelu PU, Gupta V, Dixit NM.

Virology. 2014 Jan 20;449:224-8. doi: 10.1016/j.virol.2013.11.026. Epub 2013 Dec 10.

16.

APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells.

Batisse J, Guerrero SX, Bernacchi S, Richert L, Godet J, Goldschmidt V, Mély Y, Marquet R, de Rocquigny H, Paillart JC.

J Virol. 2013 Jun;87(11):6492-506. doi: 10.1128/JVI.03494-12. Epub 2013 Apr 10.

17.

A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.

Peng J, Ao Z, Matthews C, Wang X, Ramdahin S, Chen X, Li J, Chen L, He J, Ball B, Fowke K, Plummer F, Embree J, Yao X.

J Mol Biol. 2013 Aug 23;425(16):2840-52. doi: 10.1016/j.jmb.2013.05.015. Epub 2013 May 23.

PMID:
23707381
18.

Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.

Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK.

J Virol. 2009 Feb;83(4):1992-2003. doi: 10.1128/JVI.01621-08. Epub 2008 Nov 26.

19.

Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase.

Fribourgh JL, Nguyen HC, Wolfe LS, Dewitt DC, Zhang W, Yu XF, Rhoades E, Xiong Y.

J Virol. 2014 Mar;88(6):3309-19. doi: 10.1128/JVI.03824-13. Epub 2014 Jan 3.

20.

Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.

He Z, Zhang W, Chen G, Xu R, Yu XF.

J Mol Biol. 2008 Sep 12;381(4):1000-11. doi: 10.1016/j.jmb.2008.06.061. Epub 2008 Jun 28.

PMID:
18619467
Items per page

Supplemental Content

Write to the Help Desk